Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: Radical Upfront Surgery in Advanced Ovarian Cancer
NCT02828618Active, not recruiting
- Sponsor
- AGO Study Group
- Start
- Jul 2016
- Primary completion
- Feb 2025
- Countries
- 8
01
Overview
Randomised, open-label trial (2 arms), sponsored by AGO Study Group. Primary endpoint: Overall Survival at 5 years. Started Jul 2016; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02828618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828618.